

FILE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Hallenbeck *et al.*


Serial No. : 09/373,938

Art Unit: Unassigned

Filed : August 13, 1999

Examiner: Unassigned

For : Adenoviral Vectors Including DNA Sequences Encoding
Angiogenic Inhibitors



Commissioner of Patents & Trademarks
Washington, D.C. 20231

Attn: Application Processing Division
Customer Correction Branch

REQUEST TO CORRECT FILING RECEIPT

SIR:

Applicants request that the filing receipt (a copy of which is attached) be corrected. Please correct the first word of the title from "ABENOVIRAL" to read: "ADENOVIRAL".

Please issue a corrected filing receipt as requested above.

Also, enclosed is a self-addressed postage paid postcard.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Assistant Commissioner for Patents.

Washington, DC 20231, Attention: Application
Processing Division, Customer Correction Branch

Raymond J. Lillie 1/12/2000
Raymond J. Lillie, Esq. Date

Respectfully submitted,

Raymond J. Lillie

Reg. No. 31,778

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN

Six Becker Farm Road
Roseland, NJ 07068

FILING RECEIPT
CORRECTED



UNITED STATES DEPARTMENT OF COMMERCE
Pat nt and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

RT

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/373,938	08/13/99	1646	\$1,088.00	271010-445	18	31	1

ELLIOTT M OLSTEIN ESQ
C/O CARELLA BYRNE BAIN GILFILLAN CECCHI
STEWART & OLSTEIN
6 BECKER FARM ROAD
ROSELAND NJ 07068



Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice," the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) PAUL HALLENBECK, GAITHERSBURG, MD; CHEAUYUN THERESA CHEN, ELLICOTT CITY, MD.

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 09/21/99

TITLE

ADENOVIRAL VECTORS INCLUDING DNA SEQUENCES ENCODING ANGIOGENIC INHIBITORS

PRELIMINARY CLASS: 435

ADENOVIRAL

DATE RECEIVED:	11/10/99
DATES ENTERED:	
1)	
2)	
3)	
4)	
5)	
6)	
DOCKETED BY:	<i>pm</i>

DATA ENTRY BY: JONES, ANGELONA D. TEAM: 03 DATE: 11/03/99

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184.
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE ---- The Following Information about the Filing Receipt:

The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

The words "new," "improved," "improvement," "improvements in or relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement.

The title may be truncated if it consists of more than 4 lines of 70 characters each (letters and spaces combined).

The inventor information may be truncated if the family name consists of more than 25 characters (letters and spaces combined) and if the given name consists of more than 25 characters (letters and spaces combined). The inventor's residence allows for up to 40 characters (letters and spaces combined).

The docket number allows a maximum of 12 characters.

If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Customer Address may have been modified to conform to U.S. Postal rules.

Please direct correction, including a copy of your Filing Receipt, to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Employee: _____

Team: _____

Date: 4/17/00

APR 20 2000

To: Technology Center CP2/1646

TECH CENTER 1600/2900

From: Dora Stroud, Supervisor
OIPE Customer Service
Charge Location 0350

AS
M.P.

Subject: Customer Requests

Serial Number: 09/373938

File Location: _____

The attached request for a corrected file receipt has been completed. Please forward the case to OIPE, Customer Service, CP2-6th Floor.

If you decide to keep the case, assign the request a paper number, endorse contents, punch holes in the documents, and replace the old Bib Data sheet with the updated version in the center of the file.

Your cooperation is greatly appreciated.